Bowman Cox
Executive Editor
Washington, DC
Bowman Cox leads the Pink Sheet's coverage of pharmaceutical manufacturing quality issues. He writes and edits articles on the challenges and opportunities that developments in science, technology and regulatory policy pose to drug manufacturers and their quality organizations.
Latest From Bowman Cox
McKesson Tapped For COVID-19 Vaccine Kits To Meet 1 October Distribution Goal
US HHS turns to COVID-19 vaccine distributor to assemble vaccine administration kits, citing revised vaccine delivery schedule.
Continuous Manufacturing Centers Of Excellence Measure Resurfaces In US House
Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.
COVID-19 Shows US FDA Why It Needs To Know Supply Chain’s Current And Surge Capacities
Agency begins gathering manufacturing plant data to prepare for disruptions that can drain inventories over a weekend.
US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?
US FDA Assesses Over 500 Biopharma Plants Remotely Via Records Review; Refines Process
Agency may share outcomes of remote record reviews in lieu of inspections at US and foreign facilities.
WHO Proposes Reference Standard For Adventitious Virus Detection
Emerging global standard could speed testing of biologics and gene therapies for stray viral particles, while sparing laboratory animals.